



KEEPING UP WITH ADVANCES IN MS:

CASES IN DIAGNOSIS AND TREATMENT, A CASE-BASED ROADMAP FOR IMPROVED PATIENT OUTCOMES IN MULTIPLE SCLEROSIS

Study Companion

REFERENCES

1. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. *Nat Rev Drug Discov.* 2019;18(12):905-922. doi:10.1038/s41573-019-0035-2
2. Newsome SD, Aliotta PJ, Bainbridge J, et al. CME/CNE Article: A framework of care in multiple sclerosis, part 1: Updated disease classification and disease-modifying therapy use in specific circumstances. *Int J MS Care.* 2016;18(6):314-323. doi:10.7224/1537-2073.2016-051
3. Olek MJ. Multiple sclerosis. *Ann Intern Med.* 2021;174(6):ltc81-itc96. doi:10.7326/AITC202106150
4. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2
5. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler.* 2008;14(9):1157-1174. doi:10.1177/1352458508096878
6. Aharony SM, Lam O, Corcos J. Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. *Can Urol Assoc J.* 2017;11(1-2):61-64. doi:10.5489/cuaj.4058
7. Bowen JD. Highly aggressive multiple sclerosis. *Continuum (Minneapolis, Minn).* 2019;25(3):689-714. doi:10.1212/CON.0000000000000731
8. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nat Rev Neurol.* 2019;15(5):287-300. doi:10.1038/s41582-019-0170-8
9. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. *Curr Opin Neurol.* 2018;31(6):752-759. doi:10.1097/WCO.0000000000000622
10. Mayer L, Kappos L, Racke MK, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. *Mult Scler Relat Disord.* 2019;30:236-243. doi:10.1016/j.msard.2019.01.044
11. Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. *Lancet.* 2017;389(10076):1347-1356. doi:10.1016/S0140-6736(16)32388-1
12. Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. *Lancet Neurol.* 2019;18(10):973-980. doi:10.1016/S1474-4422(19)30151-6
13. Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. *Curr Treat Options Neurol.* 2021;23(4):11. doi:10.1007/s11940-021-00666-4
14. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(17):789-800. doi:10.1212/WNL.0000000000005345
15. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347
16. CMSC Practical Guidelines for the Selection of Disease Modifying Therapies in MS. Published 2019. Accessed May 24, 2022. <https://cmscscholar.org/cmsc-practical-guidelines-for-the-selection-of-disease-modifying-therapies-in-ms/>